Skip to main content
SINPHAR logo

SINPHAR — Investor Relations & Filings

Ticker · 1734 ISIN · TW0001734002 TW Manufacturing
Open in API
Filings indexed 1,600 across all filing types
Latest filing 2024-06-07 Regulatory Filings
Country TW Taiwan
Listing TW 1734

About SINPHAR

www.sinphar.com

Sinphar Pharmaceutical Co., Ltd. is a vertically integrated pharmaceutical group specializing in the research, development, manufacturing, and distribution of therapeutic medicines, nutraceuticals, and medical cosmetics. Established in 1977, the company produces a diverse range of products, including Western and Chinese pharmaceuticals, specialized oncology drugs, and health supplements. Sinphar operates advanced R&D facilities and an ISO 17025-certified laboratory, leveraging high-precision technology for product innovation and quality assurance. Its business model encompasses proprietary brand management alongside professional OEM and ODM services for international markets. Key areas of expertise include the development of cancer treatments, functional health foods, and medical-grade skincare. Through its global marketing network and dedicated retail counters, Sinphar provides comprehensive healthcare solutions focused on life, health, and technology.

Recent filings

Filing Released Lang Actions
113年5月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (杏輝) providing information about fund loans and endorsement guarantees for the current and previous month, including cumulative balances and limits. It is a regulatory disclosure of financial data related to guarantees and loans, but it is very short (624 characters) and does not contain comprehensive financial statements or detailed analysis. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It is also not an announcement of a report publication. The content fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-06-07 Chinese
113年5月營業收入
Interim / Quarterly Report Classification · 95% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 杏輝, presented in a tabular format with explanations about accounting standards and reporting practices. It contains actual financial data for May 2024 (民國113年05月) and cumulative year-to-date figures, including comparisons to the previous year. The document is 768 characters long, which is short but contains substantive financial data rather than just an announcement or a link to a report. It is not a full annual or interim report but a periodic financial summary with key financial metrics. This fits the definition of an Interim / Quarterly Report (IR), as it provides comprehensive financial data for a period shorter than a full fiscal year and is not merely an announcement or certification. Therefore, the appropriate classification is IR with high confidence.
2024-06-07 Chinese
代重要子公司杏輝天力(杭州)藥業有限公司公告法定代表人變動
Board/Management Information Classification · 100% confidence The document is a short announcement (670 characters) about a change in the legal representative of a major subsidiary company. It includes details such as old and new representative names, dates, and reasons for the change. There is no financial data, no mention of financial results, reports, or regulatory filings beyond this management change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in company board or senior management. The document is not a report or a regulatory filing but a specific management change notice.
2024-06-07 Chinese
代重要子公司SUETIC BIOTECH INC.公告董事辭任
Board/Management Information Classification · 100% confidence The document is a short announcement (641 characters) about a change in the board or management of a company, specifically the resignation of a director at a subsidiary. It includes details such as the name of the person resigning, their position, and the effective date. There is no financial data, no mention of a report being attached or published, and no regulatory certification. This fits the category of Board/Management Information (MANG).
2024-06-07 Chinese
代重要子公司杏輝天力(杭州)藥業有限公司 決議解除經理人競業禁止案
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (杏輝) regarding a board resolution to permit a key manager to engage in competitive business activities. It includes details about the decision date, the manager's name and position, the scope and duration of permitted competitive activities, and the impact on the company. There are no financial statements, no mention of a report being attached or published, and no indication of this being a full report or presentation. The content fits the category of a regulatory announcement about management decisions rather than a financial report or meeting material. Therefore, it best fits the category of Regulatory Filings (RNS).
2024-06-07 Chinese
代重要子公司杏輝天力(杭州)藥業有限公司公告總經理變動
Board/Management Information Classification · 100% confidence The document is a short announcement (768 characters) about a change in the general manager of a major subsidiary company. It includes details such as the old and new general manager names, dates, and reasons for the change. There is no financial data, no report attached or referenced, and it concerns management personnel changes. This fits the category of Board/Management Information (MANG).
2024-06-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.